Results 41 to 50 of about 249,854 (357)
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]
, 2018 © 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki +3 more
core +2 more sources
Antiplatelet agents for preventing pre-eclampsia and its complications.
Cochrane Database of Systematic Reviews, 2019 BACKGROUND Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that
L. Duley +4 more
semanticscholar +1 more source
Antithrombotics from the Sea: Polysaccharides and Beyond
Marine Drugs, 2019 Marine organisms exhibit some advantages as a renewable source of potential drugs, far beyond chemotherapics. Particularly, the number of marine natural products with antithrombotic activity has increased in the last few years, and reports show a wide ...
Francisca Carvalhal +5 more
doaj +1 more source
An investigation of the antiplatelet effects of succinobucol (AGI-1067) [PDF]
, 2016 Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects. Given the importance of oxidant stress in modulating platelet–platelet and platelet–vessel wall interactions, the aim of this study was to establish if antioxidant ...
Gnanadesika, Sukanya +3 more
core +1 more source
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]
, 2020 Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P +17 more
core +2 more sources
Journal of the American Medical Association (JAMA), 2019 Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option.
Hirotoshi Watanabe +34 more
semanticscholar +1 more source
Stroke and vascular neurology, 2022 Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review aimed to highlight the current evidence and recommendations of antiplatelet therapy for stroke prevention.
Jay Shah, Shimeng Liu, Wengui Yu
semanticscholar +1 more source
Antiplatelet drug interactions [PDF]
Journal of Internal Medicine, 2010 Abstract. Mackenzie IS, Coughtrie MWH, MacDonald TM, Wei L. (Medicines Monitoring Unit (MEMO); and Centre for Oncology & Molecular Medicine, Division of Medical Sciences, University of Dundee, Ninewells Hospital & Medical School; Dundee, UK). Antiplatelet drug interactions (Review‐Symposium).
Mackenzie, I. S. +3 more
openaire +3 more sources
Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials [PDF]
, 2009 <p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with
Cucchiara, B. +8 more
core +1 more source
Frontiers in Cardiovascular Medicine, 2022 Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI).
A. Nguyen +4 more
semanticscholar +1 more source